Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated April 14, 2026, serves as a transaction notification for the month of April 2026. The document discloses share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan. No operational or financial performance data for the reporting period is included in this specific filing.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It solely reports on specific equity transactions executed on April 13, 2026, on the London Stock Exchange (XLON).
| Transaction Date | Instrument | Price per Share | Total Volume |
|---|---|---|---|
| 2026-04-13 | Ordinary Shares (ISIN: GB00BN7SWP63) | £21.7087 | 84 Shares (Aggregated) |
Material Changes
This filing does not contain comparative financial data or material changes to the company's business operations versus prior periods. It is a regulatory disclosure of insider share acquisitions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions described are routine acquisitions under the Share Reward Plan, consisting of partnership shares and matching shares.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs and PCAs (84 shares total across 8 individuals).
- Confirm the transaction price of £21.7087 per share against the market price on April 13, 2026.
- Review the specific roles of the individuals involved, including the CFO (Julie Brown), CEO of ViiV Healthcare (Deborah Waterhouse), and President of Europe (Lynn Baxter).
- Note that this filing does not reflect the company's overall financial health; refer to Form 20-F for comprehensive financial statements.